SCAN: Standardized Centralized Alzheimer's and Related Dementias Neuroimaging

SCAN：标准化集中式阿尔茨海默病和相关痴呆症神经影像学

• 批准号: 10335694
• 负责人: CLIFFORD R. JACK
• 金额: $ 64.16万
• 依托单位: UNIVERSITY OF CALIFORNIA BERKELEY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-05-01 至 2026-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10335694
• 关键词: Address; Age; Alzheimer' s Disease; Alzheimer' s disease diagnosis; Alzheimer' s disease pathology; Alzheimer' s disease related dementia; Alzheimer’s disease biomarker; Amyloid; Autopsy; Award; Big Data; Biological; Biological Markers; Brain imaging; Certification; Clinical; Cognitive; Cohort Studies; Communication; Communities; Complement; Consent; Consent Forms; Data; Data Set; Databases; Development; Diagnosis; Differential Diagnosis; Disease; Early Diagnosis; Epidemiology; Ethnic Origin; Etiology; Frontotemporal Dementia; Funding; Genetic; Genetic Diseases; Goals; Grant; Heterogeneity; Image; Individual; Infrastructure; Injections; Investigation; Ligands; Link; Machine Learning; Magnetic Resonance Imaging; Methods; Modality; Nature; Neurodegenerative Disorders; Parents; Parkinson Disease; Participant; Pathologic Processes; Patient Recruitments; Patients; Phenotype; Plasma; Positron-Emission Tomography; Procedures; Progressive Supranuclear Palsy; Protocols documentation; Race; Recommendation; Research; Research Personnel; Resources; Risk; Sample Size; Services; Site; Standardization; Stream; Sum; Time; Time Study; Tracer; Traction; Validation; Vascular Diseases; Wisconsin; Work; amyloid pathology; base; clinical Diagnosis; corticobasal syndrome; data sharing; demographics; disease phenotype; flexibility; imaging modality; improved; innovation; large datasets; large scale data; mild cognitive impairment; neuroimaging; normal aging; pre-clinical; programs; prospective; tau Proteins; virtual; willingness

PROJECT SUMMARY Amyloid PET is central to a biological definition of Alzheimer’s disease (AD) and has been integrated heavily into the research setting since the first PIB-PET scans in 2004. The SCAN-Amyloid Legacy (SCAN-AL) Project will leverage already established research programs (SCAN, NACC, LONI) along with extensive work that has been conducted over the previous 15 years at the ADRC site level to implement and collect expensive and valuable amyloid PET data on ADRC research participants. The ultimate goal of this effort is to curate and harmonize pre-existing amyloid PET data collected across ADRC sites to create a large-scale resource that can be disseminated to the ADRC community for use in various research endeavors. More specifically, during this award period we will aim to curate 3000 amyloid PET scans, which is similar to the number of amyloid PET scans currently available through ADNI, and to link this data to extensive data already available on these participants (clinical and cognitive data, biofluid data, postmortem data, etc). Whereas the parent SCAN award focuses on processing of prospective PET and MRI data utilizing rigorous standardization methods both during image acquisition and post-acquisition processing, SCAN-AL will allow more flexibility to enable the specific goal of obtaining legacy amyloid PET data on as many unique ADRC Clinical Core participants as possible. This work is significant because we are quickly approaching 2025 and still lack a disease modifying treatment for AD. The data leveraging proposed herein extends the value of the considerable funding has been directed towards cohort studies of AD to contribute towards this goal of curing AD by 2025. Increasing the utilization of pre-existing amyloid PET dataset across ADRCs is particularly significant and unique compared to other large-scale efforts such as ADNI, given the heterogeneity in ADRC participants both in terms of clinical diagnoses and demographics. Whereas ADNI focuses specifically on normal aging, mild cognitive impairment (MCI), and AD diagnoses, the ADRC program recruits participants spanning a range of neurodegenerative diseases that reflect the focus and expertise of local investigators, such as vascular disease, frontotemporal dementia, progressive supranuclear palsy, corticobasal syndrome, Parkinson’s, etc. Further, the ADRC program is unique in that a broad range of demographics regarding race, ethnicity, and age are reflected. We anticipate that the SCAN-AL Project will contribute to timely scientific opportunities related to the validation of plasma AD biomarkers, support innovative analyses that require large datasets such as work with genetics and machine learning, as well as enable the investigation of rare phenotypes that are difficult to collect at one site alone. This effort will provide ample opportunities to AD investigators and complement the efforts of the SCAN initiative.

项目摘要 淀粉样蛋白宠物是对阿尔茨海默氏病（AD）生物学定义的核心 自2004年第一次PIB-PET扫描以来的研究环境。Scan-Amyloid Legacy（Scan-Al）项目 将利用已经建立的研究计划（SCAN，NACC，LONI），以及广泛的工作 是在过去15年中在ADRC站点级别进行的，以实施和收集昂贵的 有价值的ADRC研究参与者的淀粉样蛋白宠物数据。这项努力的最终目标是策划和 协调跨ADRC站点收集的淀粉样蛋白PET数据，以创建大规模资源 可以将其传播到ADRC社区，以用于各种研究努力。更多的 具体而言，在此奖励期间，我们将旨在策划3000个淀粉样蛋白PET扫描，这类似于 目前可以通过ADNI获得的淀粉样PET扫描数量，并将这些数据链接到大量数据 可用于这些参与者（临床和认知数据，生物流体数据，验尸数据等）。而 家长扫描奖的重点是处理潜在的宠物和MRI数据，利用严格的标准化 在获取和收购后处理期间的方法，Scan-al将允许更具灵活性 启用有关许多独特的ADRC临床核心获取遗产淀粉样蛋白PET数据的具体目标 参与者。这项工作很重要，因为我们迅速接近2025，但仍然缺乏 修改AD的疾病治疗。本文提出的利用数据扩展了 大量资金已针对AD的队列研究，以实现这一目标 在2025年之前固化AD。尤其是在ADRC中增加淀粉样蛋白PET数据集的利用尤其是 鉴于ADRC的异质性，与其他大规模努力（例如ADNI）相比，重要而独特 参与者在临床诊断和人口统计学方面。而ADNI专门针对正常 衰老，轻度认知障碍（MCI）和AD诊断，ADRC计划报告了参与者 反映了当地研究者的重点和专业知识的一系列神经退行性疾病，例如血管 疾病，额颞痴呆，进行性胸骨性麻痹，皮质综合征，帕金森氏症等。 此外，ADRC计划是独一无二的，因为有关种族，种族和年龄的广泛人口统计 被反映。我们预计扫描项目将有助于及时的科学机会 血浆广告生物标志物的验证，支持需要大型数据集的创新分析 借助遗传学和机器学习，并实现了难以进行的稀有表型的投资 独自在一个地点收集。这项努力将为广告调查人员提供足够的机会，并完成 扫描计划的努力。